Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Smith & Nephew SNATS, Inc.

Stage 4 · Declining · week 8

As of Oct 22, 2026, Smith & Nephew SNATS is in Stage 4, the downtrend phase, now in week 8 (since Aug 27, 2026). It closed at $30.88, 14.7% below its 52-week high and above its 200-day average, which is falling.

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. More about the company

$30.88
+5.64% today
$12.9B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is SNN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 16w
S2 30w
S3 13w
S4 15w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 3w → S4 13w → S1 10w → S2 5w → S3 3w → S4 9w → S1 2w → S2 16w → S3 6w → S4 11w → S1 7w → S2 30w → S3 13w → S2 8w → S3 2w → S4 15w → S1 3w → S4 8w current
Total tracked: 165 weeks across 18 stage runs.

SNN among Medical Devices59th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…59SNNStage 4 · wk 844+16.5%
vs 52W High
-14.7%
$26.27 lo$36.19 hi
14.7% below 52W high, failed near resistance
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 8
1w13w26w
Week 8, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
0.7%
200 DMA: $30.68 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
1.12x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↗ ⇈
Short-term trend rising gently, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+16.5%
3M
+2.2%
6M
-2.1%
YTD
-3.5%
1Y
-13.2%
Scan Membership
Breakout Watch
Latest: 2025-04-14
8 appearances in last 60 days. First seen: 2019-01-04.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 8 · Vol 1.12x
2026-10-21S4
Wk 8 · Vol 0.56x
2026-10-20S4
Wk 8 · Vol 0.55x
2026-10-19S4
Wk 8 · Vol 0.43x
2026-10-16S4
Wk 8 · Vol 0.88x
2026-10-15S4
Wk 7 · Vol 1.32x
2026-10-14S4
Wk 7 · Vol 0.57x
2026-10-13S4
Wk 7 · Vol 0.64x
2026-10-12S4
Wk 7 · Vol 0.65x
2026-10-09S4
Wk 7 · Vol 0.63x
2026-10-08S4
Wk 6 · Vol 0.66x
2026-10-07S4
Wk 6 · Vol 0.64x
Moving averages & range
50 DMA
$28.01
200 DMA
$30.68
52W High
$36.19
52W Low
$26.27
5D Low
$28.84
Resistance levels (recent highs)
20d High
$30.88
60d High
$31.95
120d High
$32.28
250d High
$36.04
Next resistance
+3.5%
to 60d High
P/E (TTM)
21.0
Forward 12.8
Earnings Growth (YoY)
+5.7%
Revenue +4.6%
ROE
+11.9%
Profit margin +10.1%
Dividend Yield
2.72%
P/B 12.7

Smith & Nephew SNATS: quick answers

What stage is Smith & Nephew SNATS in?

As of Oct 22, 2026, Smith & Nephew SNATS (SNN) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 27, 2026 and is in week 8. What the four stages mean

Is Smith & Nephew SNATS in an uptrend?

No. Smith & Nephew SNATS is in a Stage 4 downtrend. It trades 0.7% above its 200-day average, which is falling.

How far is Smith & Nephew SNATS from its 52-week high?

Smith & Nephew SNATS closed at $30.88 on Oct 22, 2026, 14.7% below its 52-week high of $36.19. Its 52-week low is $26.27.

How has Smith & Nephew SNATS performed over the past year?

As of Oct 22, 2026, Smith & Nephew SNATS is down 13.2% over the past year and down 3.5% so far in 2026.

Which sector and industry is Smith & Nephew SNATS in?

Smith & Nephew SNATS is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.